⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 17, 2026ESMO OpenOpen Access

454P MTAP gene expression as a novel biomarker in neuroendocrine lung neoplasms

Luca Roma M.M. Brune Nikolaus Deigendesch Sarp Uzun Obinna Chijioke S. Savic Prince M. Haberecker L. Bubendorf

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the role of MTAP gene expression as a novel biomarker in neuroendocrine lung neoplasms and its association with patient survival.
Analyzed gene expression levels in lung neuroendocrine neoplasm subtypes.
Correlated SLFN11 expression with overall survival rates and Ki67 levels.
Compared expression levels across different neuroendocrine tumor types.
In small cell lung cancer (SCLC), higher SLFN11 expression correlated with improved overall survival (13.9 months vs 6.8 months).
In LCNEC, higher SLFN11 expression indicated worse survival outcomes.
SLFN11 expression levels were highest in SCLC, followed by LCNEC, and lowest in TC/AC.

Implication

Analysis shows MTAP gene expression is a potential biomarker for survival in neuroendocrine lung neoplasms, suggesting clinical relevance.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roma et al. (2026) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672b06 https://doi.org/10.1016/j.esmoop.2026.106768

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1456P NK cell heterogeneity is associated with chemoimmunotherapy response in small cell lung cancer patientsOriginal Research · 2026
2MET and SLFN11 as a Players in the SCLC Molecular Subtyping GamePrognostic Study · 2025 · 4 citations
3Integrated Bioinformatic and Experimental Analysis of SLFN11 Expression and Clinical Significance in Locally Advanced Rectal CancerOriginal Research · 2026
4Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer—A Prospective Pilot Study2024 · 11 citations
5Schlafen 11 as a prognostic and potentially predictive biomarker in soft tissue sarcoma: evidence from a real-world cohortOriginal Research · 2026 · 1 citations

More related papers

Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets2024
Neuroendocrine features in small cell lung cancer (SCLC) and associations with platinum-sensitivity, metastatic tropism, and overall survival.2024
PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer2016

More from ESMO Open

Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measureTue,
Adjuvant therapy for RCC: considerations beyond survival metricsTue,